ArticleScientific reports2025
METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NMolecular neurobiology · 2026Article
- METTL3 in esophageal cancer: Current insights into molecular mechanisms, subtype heterogeneity and targeted therapy prospects (Review).International journal of oncology · 2026Review
- Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.Biomolecules · 2026Review
- Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.Experimental hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study was designed to illustrate the mechanism underlying the up-regulation of LINC00857 expression and to identify novel molecular targets for the treatment of ovarian cancer (OC). The LINC00857 and methyltransferase-like 3 (METTL3) expression levels were observed in clinical OC tissues and cells, and their correlation within tissues was analyzed. To further explore the relationship between LINC00857 and METTL3, a combined transfection of pcDNA3.1-LINC00857 and METTL3 siRNA was performed. Subsequently, cell invasion, viability, migration, and sphere-forming capabilities were assessed using Transwell, Cell Counting Kit-8, scratch and sphere-formation assays. Furthermore, western blot analysis was conducted to determine the expression of proteins related to cancer cell stemness and the yes-associated protein (YAP) pathway. The relationship between LINC00857 and METTL3 was verified using the MeRIP-qPCR kit, RNA pull-down assay and RNA stability assay. Both LINC00857 and METTL3 demonstrated high expression levels in OC cells and tissues, with a positive correlation observed in clinical tissues. When knocking down the LINC00857 expression level, the invasion, migration, proliferation, and sphere-forming capabilities of cells were all notably reduced. Knocking down LINC00857 expression also markedly decreased the activity of the YAP pathway and the expression of proteins related to cancer cell stemness. Overexpression of LINC00857 yielded opposite effects. When knocking down METTL3, the stability of LINC00857 and the modification level of N6-methyladenosine were remarkably decreased. Moreover, there was interaction between METTL3 and LINC00857. METTL3-mediated N6-methyladenosine modification of LINC00857 enhanced metastasis and stemness of OC cells via activating the YAP-TEA domain transcription factor pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.